Billy Evans, partner of Theranos founder Elizabeth Holmes, is launching a new startup focused on “human health optimization” through innovative blood testing. As reported on 2025-05-11, this venture, named Haemanthus, aims to revolutionize health diagnostics.
- Billy Evans starts new health startup Haemanthus.
- Company focuses on blood, saliva, urine testing.
- Plans to begin with pet health market.
- Haemanthus seeks over $50 million funding.
- Echoes Theranos' controversial testing promises.
- Investor Jim Breyer declined to invest again.
According to The New York Times, Haemanthus has developed a machine that utilizes lasers to analyze blood, saliva, and urine samples for detecting cancer and infections. Initially targeting pet health, the company plans to expand its services to humans while seeking over $50 million in funding.
This ambitious pitch echoes the controversial promises made by Theranos, which faced scrutiny for its technology. With Holmes currently serving an 11-year prison sentence for fraud, can Evans successfully distance Haemanthus from its predecessor’s legacy?
The emergence of Haemanthus raises critical questions about the future of health technology. Will investors trust a new venture linked to a notorious past? The global landscape for health startups is increasingly competitive, prompting a closer examination of innovation and ethics.
- Investors are wary due to past failures, particularly in the U.S.
- Emerging markets in Asia-Pacific may be more receptive to innovative health solutions.
- Europe’s regulatory environment could influence Haemanthus’ operational strategy.
- Pet health as a starting point may attract initial funding and consumer interest.
As Haemanthus prepares to enter the market, it will be crucial for the company to establish credibility and demonstrate the efficacy of its technology. The global health landscape awaits its next move.
